CTLA-4 antibody ipilimumab negatively affects CD4+ T-cell responses in vitro
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1432-0851
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
CTLA-4 antibody ipilimumab negatively affects CD4+ T-cell responses in vitro ; volume:68 ; number:8 ; day:22 ; month:7 ; year:2019 ; pages:1359-1368 ; date:8.2019
Cancer immunology immunotherapy ; 68, Heft 8 (22.7.2019), 1359-1368, 8.2019
- Urheber
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00262-019-02369-x
- URN
-
urn:nbn:de:101:1-2019122801584245779332
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Rosskopf, Sandra
- Leitner, Judith
- Zlabinger, Gerhard J.
- Steinberger, Peter
- SpringerLink (Online service)
Ähnliche Objekte (12)
FOSL1-mediated LINC01566 negatively regulates CD4+ T-cell activation in myasthenia gravis
Functional characterization of rat CTLA-4 and CD25+CD4+ regulatory T-cells
Functional characterization of rat CTLA-4 and CD25+CD4+ regulatory T cells
Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus
Anti‐TNF treatment negatively regulates human CD4 + T‐cell activation and maturation in vitro, but does not confer an anergic or suppressive phenotype
Ipilimumab treatment decreases circulating Tregs and GrMDSC while enhancing CD4+ T cell activation
CD4 T-cell help sustains distinct subpopulations in functional and dysfunctional CD8 T-cell responses.
CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)
The transcription factor Zfp281 sustains CD4+ T lymphocyte activation through directly repressing Ctla-4 transcription
m6A methyltransferase METTL3 programs CD4+ T-cell activation and effector T-cell differentiation in systemic lupus erythematosus
CD160 isoforms and regulation of CD4 and CD8 T-cell responses
Identification of clinically relevant CD4+ T-cell epitopes from HCMV antigens
FOSL1-mediated LINC01566 negatively regulates CD4+ T-cell activation in myasthenia gravis
Functional characterization of rat CTLA-4 and CD25+CD4+ regulatory T-cells
Functional characterization of rat CTLA-4 and CD25+CD4+ regulatory T cells
Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus
Anti‐TNF treatment negatively regulates human CD4 + T‐cell activation and maturation in vitro, but does not confer an anergic or suppressive phenotype
Ipilimumab treatment decreases circulating Tregs and GrMDSC while enhancing CD4+ T cell activation
CD4 T-cell help sustains distinct subpopulations in functional and dysfunctional CD8 T-cell responses.
CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)
The transcription factor Zfp281 sustains CD4+ T lymphocyte activation through directly repressing Ctla-4 transcription
m6A methyltransferase METTL3 programs CD4+ T-cell activation and effector T-cell differentiation in systemic lupus erythematosus
CD160 isoforms and regulation of CD4 and CD8 T-cell responses
Identification of clinically relevant CD4+ T-cell epitopes from HCMV antigens
FOSL1-mediated LINC01566 negatively regulates CD4+ T-cell activation in myasthenia gravis
Functional characterization of rat CTLA-4 and CD25+CD4+ regulatory T-cells
Functional characterization of rat CTLA-4 and CD25+CD4+ regulatory T cells
Immunoregulatory soluble CTLA-4 modifies effector T-cell responses in systemic lupus erythematosus
Anti‐TNF treatment negatively regulates human CD4 + T‐cell activation and maturation in vitro, but does not confer an anergic or suppressive phenotype
Ipilimumab treatment decreases circulating Tregs and GrMDSC while enhancing CD4+ T cell activation
CD4 T-cell help sustains distinct subpopulations in functional and dysfunctional CD8 T-cell responses.
CTLA4 promoter methylation predicts response and progression-free survival in stage IV melanoma treated with anti-CTLA-4 immunotherapy (ipilimumab)
The transcription factor Zfp281 sustains CD4+ T lymphocyte activation through directly repressing Ctla-4 transcription
m6A methyltransferase METTL3 programs CD4+ T-cell activation and effector T-cell differentiation in systemic lupus erythematosus
CD160 isoforms and regulation of CD4 and CD8 T-cell responses